ABI

59.02

+0.27%↑

CDI

433.8

-0.05%↓

DG

126.2

+2.06%↑

AD

40.04

-1.93%↓

HEIO

61.15

-0.41%↓

ABI

59.02

+0.27%↑

CDI

433.8

-0.05%↓

DG

126.2

+2.06%↑

AD

40.04

-1.93%↓

HEIO

61.15

-0.41%↓

ABI

59.02

+0.27%↑

CDI

433.8

-0.05%↓

DG

126.2

+2.06%↑

AD

40.04

-1.93%↓

HEIO

61.15

-0.41%↓

ABI

59.02

+0.27%↑

CDI

433.8

-0.05%↓

DG

126.2

+2.06%↑

AD

40.04

-1.93%↓

HEIO

61.15

-0.41%↓

ABI

59.02

+0.27%↑

CDI

433.8

-0.05%↓

DG

126.2

+2.06%↑

AD

40.04

-1.93%↓

HEIO

61.15

-0.41%↓

Search

Fluidra SA

Slēgts

SektorsPatēriņa aizsardzības

19.42 3.85

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

18.38

Max

19.69

Galvenie mērījumi

By Trading Economics

Ienākumi

-9.6M

17M

Pārdošana

-38M

460M

P/E

Sektora vidējais

21.656

28.772

EPS

0.19

Dividenžu ienesīgums

3.23

Peļņas marža

3.775

Darbinieki

6,767

EBITDA

365M

460M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+43.08% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

3.23%

3.67%

Nākamie ieņēmumi

2026. g. 6. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-741M

3.8B

Iepriekšējā atvēršanas cena

15.57

Iepriekšējā slēgšanas cena

19.42

Ziņu noskaņojums

By Acuity

50%

50%

53 / 131 Rangs Consumer defensive

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

Fluidra SA Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 23. marts 23:47 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

2026. g. 23. marts 22:55 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

2026. g. 23. marts 21:51 UTC

Iegādes, apvienošanās, pārņemšana

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

2026. g. 23. marts 23:59 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 23. marts 23:59 UTC

Tirgus saruna

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

2026. g. 23. marts 23:50 UTC

Tirgus saruna

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

2026. g. 23. marts 23:37 UTC

Tirgus saruna

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

2026. g. 23. marts 22:42 UTC

Tirgus saruna
Galvenie ziņu notikumi

Global Equities Roundup: Market Talk

2026. g. 23. marts 22:42 UTC

Tirgus saruna
Galvenie ziņu notikumi

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

2026. g. 23. marts 22:40 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

2026. g. 23. marts 22:23 UTC

Tirgus saruna

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

2026. g. 23. marts 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

2026. g. 23. marts 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

2026. g. 23. marts 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

2026. g. 23. marts 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

2026. g. 23. marts 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

2026. g. 23. marts 22:19 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

2026. g. 23. marts 22:19 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

2026. g. 23. marts 22:18 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

2026. g. 23. marts 22:15 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

2026. g. 23. marts 22:08 UTC

Tirgus saruna

Ebos Needs to Reset Its Gearing Targets -- Market Talk

2026. g. 23. marts 21:42 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 23. marts 21:42 UTC

Tirgus saruna

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

2026. g. 23. marts 21:32 UTC

Peļņas

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

2026. g. 23. marts 21:32 UTC

Peļņas

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

2026. g. 23. marts 21:32 UTC

Peļņas

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

2026. g. 23. marts 21:10 UTC

Galvenie ziņu notikumi

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

2026. g. 23. marts 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 23. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 23. marts 20:50 UTC

Tirgus saruna
Peļņas
Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Fluidra SA Prognoze

Cenas mērķis

By TipRanks

43.08% augšup

Prognoze 12 mēnešiem

Vidējais 26.87 EUR  43.08%

Augstākais 31 EUR

Zemākais 21.5 EUR

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Fluidra SA — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

6 ratings

4

Pirkt

1

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

20.12 / 20.22Atbalsts un pretestība

Īstermiņā

Bearish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Strong Bearish Evidence

Noskaņojums

By Acuity

53 / 131 Rangs Patēriņa aizsardzības

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Fluidra SA

Fluidra, S.A., together with its subsidiaries, manufactures, distributes, and markets accessories and machinery for swimming-pools, irrigation and water treatment, and purification for residential and commercial pool market worldwide. The company provides basic pool fittings, which includes ladders, showers, pumps, valves, filters, heaters, grilles, water lighting, cleaning accessories, and others; robotic pool cleaners, pool covers, fire and water features, slides, springboards, and connected products; pool fittings spare parts; above-ground pools, and natural ponds and pools; and swim spas, saunas and steam baths, sensory showers, and Nordic baths. It also provides commercial pool and wellness water facilities for public use, including hotel and resort pools, water parks, municipal and competition pools, spa and wellness centers, fountains, lagoons, and aquariums; and develops turnkey aquatic projects. In addition, the company offers pool water treatment products; irrigation accessories for gardens; and manufactures and distributes high-end valves and accessories to build pool hydraulic circuits. It sells its products under the Astral Pool, Zodiac, Jandy, Polaris, GRE, Cepex, CTX Professional, Certikin, and Piscine Laghetto brands. The company was formerly known as Aquaria de Inv. Corp., S.L. and changed its name to Fluidra, S.A. in September 2007. Fluidra, S.A. was founded in 1969 and is headquartered in Sant Cugat del Vallès, Spain.
help-icon Live chat